ClinicalTrials.gg
CompletedNCT04258839Updated May 30, 2024Results posted

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

A Phase 3 interventional study of Brexpiprazole in Irritability Associated With Autism Spectrum Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 28 sites in United States. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-05-30.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
95
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd. — none open to participants now, none under way, none of them phase 3. Autistic Disorder · Otsuka Holdings Co., Ltd..

Enrollment
7th of 10
95 · median 105
Started
2020
the only one that year
Phase 3
8 of 11
none open now
Registered
11th of 11
by date

Among the 11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd., this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2020, is one of 8 in phase 3, and was the 11th registered.

Autistic Disorder

1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

None of the 11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd. is open now. The open studies under Autistic Disorder, anywhere →

Where they have run

Who these studies take

Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Autistic Disorder by Otsuka Holdings Co., Ltd. as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and tolerability of brexpiprazole in children and adolescent participants, aged 5 to 17, with irritability associated with autism spectrum disorder.

03

Conditions studied

  • Irritability Associated With Autism Spectrum Disorder

Keywords

  • Autism
  • Autism Spectrum Disorder
  • ASD
  • Irritability
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 5 to 17 year of age or turned 18 while enrolled in the 331-201-00148 study
  • Autism Spectrum Disorder
  • Completion of 331-201-00148 trial
  • Investigator assessment

Exclusion criteria

Exclusion Criteria:

  • Did not complete treatment period or incurred significant protocol deviations during 331-201-00148 study
  • Sexually active males or female of who do not agree to practice 2 different methods of or remain abstinent during the trial and for 30 days after the last dose
  • Female with positive pregnancy test
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Brexpiprazole

    Participants received brexpiprazole based on the body weight for 26 weeks in this study. Participants with body weight \< 50 kilograms (kg), received brexpiprazole tablets orally, once daily (QD) at dose of 0.25 mg on Days 1 to 3 followed by 0.5 mg on Days 4 to 7 and 1 mg on Days 8 to 14. Based on the investigator's judgment, the dose was increased to 1 or 1.5 mg starting from Day 15 until week 26. Participants with body weight ≥ 50 kg received brexpiprazole tablet orally, QD at dose of 0.5 mg on Days 1 to 3, followed by 1.5 mg on Days 4 to 7, and 2 mg on Days 8 to 14. Based on the investigator's judgment the dose was increased to 1.5, 2, or 3 mg starting from Day 15 until week 26.

    Drug: Brexpiprazole

Interventions

  • Oral tablet; taken once daily

    Also known as: OPC-34712, LuAF41156

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded By Severity, Serious TEAEs and Trial Discontinuation Due to TEAEs

    An AE is any untoward medical occurrence in a clinical trial participant administered a medicinal product that does not necessarily have a causal relationship with the treatment. An SAE: AE that results in the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions i.e. fatal, life-threatening, result in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, and requires inpatient hospitalization or prolongation of existing hospitalization. A TEAE is defined as an AE that started after trial drug treatment; or if the event was continuous from baseline and was worsening, serious, trial drug-related, or resulted in death, discontinuation, interruption, or reduction of trial therapy. TEAEs were graded as, Mild: Discomfort noticed, but no disruption to daily activity, Moderate: Discomfort sufficient to reduce or affect normal daily activity, and Severe: Inability to work or perform normal daily activity.

    Time frame: From the first dose of study drug (in current study) up to 21 days after the last dose of study drug (up to approximately 29 weeks)

  2. Number of Participants With Potentially Clinically Relevant Abnormalities in Vital Signs

    Vital signs measurements included body weight, body temperature, systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate. Blood pressure (i.e., SBP, DBP) and heart rate were measured in the supine and standing positions after the participant had been in each position for at least 3 minutes. The participants were categorized based on the clinically relevant vital sign values as per protocol-predefined criteria. The categories with at least one participant with clinically significant value outside the normal range for vital signs are reported.

    Time frame: Baseline (current study) up to Week 26

  3. Number of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities

    Twelve-lead ECG recordings were obtained after the participant was supine and at rest for at least 5 minutes. Criteria for identifying ECG measurements of potential clinical relevance included Rate: Tachycardia (Vent ≥110 beats per minute \[bpm\]; increase ≥15bpm), Bradycardia (Vent ≤ 60bpm; decrease ≥15bpm); Rhythm: Sinus tachycardia (≥ 110bpm; an increase of ≥15 bpm), Sinus bradycardia (≤ 60bpm; a decrease of ≥15 bpm), Supraventricular premature beat (not present at baseline and present post-baseline), Conduction: Right bundle branch block (not present at baseline and present post-baseline) and ST/T Morphology: Symmetrical T-Wave Inversion (not present at baseline and present post-baseline). The categories with at least one participant with clinically relevant ECG abnormalities are reported.

    Time frame: Baseline (current study) up to Week 26

  4. Number of Participants With Potentially Clinically Relevant Laboratory Test Abnormalities

    Laboratory assessments included - serum chemistry including prolactin and thyrotropin, hematology, and urinalysis. Number of participants with potentially clinically relevant laboratory test abnormalities were reported as per criteria defined in SAP. The categories with at least one participant with clinically relevant value outside the normal range for laboratory assessments are reported.

    Time frame: Baseline (current study) up to Week 26

  5. Number of Participants With Potentially Clinically Relevant Abnormal Physical Examination Values

    Physical examination included measurement of height and the examination of the head, ears, eyes, nose, and throat (HEENT); thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae. Participants with abnormal values, as assessed by the investigator were reported.

    Time frame: Baseline (current study) up to Week 26

  6. Number of Participants With Suicidality as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS)

    Suicidality as defined as at least one occurrence of suicidal ideation or suicidal behavior, was assessed using C-SSRS. The assessment included "yes" or "no" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) \& suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings were provided for suicidal ideation: Score range of 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent), higher total scores indicate more suicidal ideation; Suicidal behavior: Score range of 0 (no suicidal behavior) to 4 (actual suicide attempt), higher total scores indicate more suicidal behavior. Number of participants with at least one occurrence of suicidal ideation or suicidal behavior was reported.

    Time frame: Baseline (current study) up to Week 26

  7. Change From Baseline in Simpson Angus Scale (SAS) Total Score at Week 2

    SAS was used to evaluate extrapyramidal symptoms (EPS). The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point Likert scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where a higher score indicates a severe condition. Negative change from baseline indicates absence of symptoms.

    Time frame: Baseline and Week 2

  8. Change From Baseline in SAS Total Score at Week 14

    SAS was used to evaluate extrapyramidal symptoms (EPS). The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point Likert scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where a higher score indicates a severe condition. Negative change from baseline indicates absence of symptoms.

    Time frame: Baseline and Week 14

  9. Change From Baseline in SAS Total Score at Week 26

    SAS was used to evaluate extrapyramidal symptoms (EPS). The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point Likert scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where a higher score indicates a severe condition. Negative change from baseline indicates absence of symptoms.

    Time frame: Baseline and Week 26

  10. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Week 2

    The AIMS is a 12-item scale. The first 10 items are rated on a Likert 5-point scale from 0 to 4 (0 = best, 4 = worst). An item score of 0, depending on specific item, means either "no abnormal Involuntary movement (AIM)" or "no incapacitation due to AIM" or "no awareness of AIM". An item score of 4 means either "severe AIM" or "severe incapacitation due to AIM" or "being aware of, and severe distress caused by AIM". Items 11 and 12 are related to dental status, taking dichotomous response: 0 = no and 1 = yes. AIMS movement score is the sum of the ratings for the first seven items with possible total scores of 0 to 28, where a higher score indicates a severe condition.

    Time frame: Baseline and Week 2

  11. Change From Baseline in AIMS Total Score at Week 14

    The AIMS is a 12-item scale. The first 10 items are rated on a Likert 5-point scale from 0 to 4 (0 = best, 4 = worst). An item score of 0, depending on specific item, means either "no abnormal Involuntary movement (AIM)" or "no incapacitation due to AIM" or "no awareness of AIM". An item score of 4 means either "severe AIM" or "severe incapacitation due to AIM" or "being aware of, and severe distress caused by AIM". Items 11 and 12 are related to dental status, taking dichotomous response: 0 = no and 1 = yes. AIMS movement score is the sum of the ratings for the first seven items with possible total scores of 0 to 28, where a higher score indicates a severe condition.

    Time frame: Baseline and Week 14

  12. Change From Baseline in AIMS Total Score at Week 26

    The AIMS is a 12-item scale. The first 10 items are rated on a Likert 5-point scale from 0 to 4 (0 = best, 4 = worst). An item score of 0, depending on specific item, means either "no abnormal Involuntary movement (AIM)" or "no incapacitation due to AIM" or "no awareness of AIM". An item score of 4 means either "severe AIM" or "severe incapacitation due to AIM" or "being aware of, and severe distress caused by AIM". Items 11 and 12 are related to dental status, taking dichotomous response: 0 = no and 1 = yes. AIMS movement score is the sum of the ratings for the first seven items with possible total scores of 0 to 28, where a higher score indicates a severe condition. A negative change from baseline indicates less symptoms.

    Time frame: Baseline and Week 26

  13. Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score at Week 2

    The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point Likert scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14. Lower scores indicate less symptoms.

    Time frame: Baseline and Week 2

  14. Change From Baseline in BARS Score at Week 14

    The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point Likert scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14. Lower scores indicate less symptoms and negative change from baseline indicate less symptoms.

    Time frame: Baseline and Week 14

  15. Change From Baseline in BARS Score at Week 26

    The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point Likert scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14. Lower scores indicate less symptoms and negative change from baseline indicate less symptoms.

    Time frame: Baseline and Week 26

  16. Percentage of Participants With Potentially Clinically Relevant Changes in Weight up to Week 14

    Percentage of participants who had significant weight gain (≥ 7% increase in body weight relative to baseline) and significant weight loss (≥ 7% decrease in body weight relative to baseline) were reported.

    Time frame: Baseline up to Week 14

  17. Percentage of Participants With Potentially Clinically Relevant Changes in Weight up to Week 26

    Percentage of participants who had significant weight gain (≥ 7% increase in body weight relative to baseline) and significant weight loss (≥ 7% decrease in body weight relative to baseline) were reported.

    Time frame: Baseline up to Week 26

  18. Time to Discontinuation Due to AE

    The time to discontinuation due to AE was defined as the total number of days between the enrolment date and the discontinuation date. The time to discontinuation was analyzed using the Kaplan Meier curve.

    Time frame: Baseline (in current study) up to 21 days post last dose of study drug (up to approximately 29 weeks)

Secondary outcomes

  1. Mean Change From Baseline to Week 26 in Aberrant Behavior Checklist - Irritability (ABC-I) Subscale Score

    The ABC is parent-reported rating scale designed to assess treatment effects on problem behavior in participants with intellectual disabilities. The ABC scale has 58 items, which divide into 5 subscales as follows:(1) Irritability, Agitation; (2) Lethargy, Social Withdrawal; (3) Stereotypic Behavior; (4) Hyperactivity, Noncompliance; and (5) Inappropriate Speech. Each of the 58 ABC items is rated on a 4-point scale (0 = not at all a problem; 1=the behavior is a problem, but slight in degree; 2=problem is moderately serious; 3=problem is severe in degree). The Irritability subscale (ABC-I) measures emotional and behavioral symptoms of ASD, including aggression toward others, deliberate self-injuriousness, temper tantrums, \& quickly changing moods. ABC-I total score is the sum of the ratings over 15 ABC items. Individual scores were summed, thus the ABC-I total score ranges from 0 to 45. Higher scores represent the worst condition. Negative change from baseline indicates less symptoms.

    Time frame: Baseline (current study), Week 26

  2. Mean Change From Baseline to Week 26 in Clinical Global Impression - Severity (CGI-S) Scale Score

    The CGI-S scale is a clinician-rated assessment that evaluates the severity of a participant's condition with a focus on symptoms of irritability on a 7-point scale. The investigator (or rater) answered the following question: "Considering your total clinical experience with this particular population, how ill was the participant at this time with regard to symptoms of irritability?" Response choices were 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The total score ranges from 0 to 7, where higher scores indicate worse condition. A negative change from baseline indicates less symptoms.

    Time frame: Baseline (current study), Week 26

07

Results

Posted May 30, 2024

Participant flow

Participants with irritability associated with autism spectrum disorder (ASD) were enrolled in the study at sites in the United States from 23 January 2020 to 16 March 2023.

Participant flow — Overall Study
MilestonePrior BrexpiprazolePrior Placebo
Started4946
Safety sample4946
Efficacy sample4846
Completed3931
Not completed1015
Withdrew: Adverse event24
Withdrew: Lack of efficacy02
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject12
Withdrew: Withdrawal by caregiver56
Withdrew: Reason not specified01

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) Graded By Severity, Serious TEAEs and Trial Discontinuation Due to TEAEs

An AE is any untoward medical occurrence in a clinical trial participant administered a medicinal product that does not necessarily have a causal relationship with the treatment. An SAE: AE that results in the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions i.e. fatal, life-threatening, result in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, and requires inpatient hospitalization or prolongation of existing hospitalization. A TEAE is defined as an AE that started after trial drug treatment; or if the event was continuous from baseline and was worsening, serious, trial drug-related, or resulted in death, discontinuation, interruption, or reduction of trial therapy. TEAEs were graded as, Mild: Discomfort noticed, but no disruption to daily activity, Moderate: Discomfort sufficient to reduce or affect normal daily activity, and Severe: Inability to work or perform normal daily activity.

Time frame:
From the first dose of study drug (in current study) up to 21 days after the last dose of study drug (up to approximately 29 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded By Severity, Serious TEAEs and Trial Discontinuation Due to TEAEs
ParticipantsPrior BrexpiprazolePrior Placebo
Participants With TEAEs2324
Participants With Mild TEAEs1519
Participants With Moderate TEAEs1112
Participants With Severe TEAEs22
Participants With Serious TEAEs21
Participants With Trial Discontinuations due to TEAEs24
PrimaryNumber of Participants With Potentially Clinically Relevant Abnormalities in Vital Signs

Vital signs measurements included body weight, body temperature, systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate. Blood pressure (i.e., SBP, DBP) and heart rate were measured in the supine and standing positions after the participant had been in each position for at least 3 minutes. The participants were categorized based on the clinically relevant vital sign values as per protocol-predefined criteria. The categories with at least one participant with clinically significant value outside the normal range for vital signs are reported.

Time frame:
Baseline (current study) up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant Abnormalities in Vital Signs
ParticipantsPrior BrexpiprazolePrior Placebo
SBP Standing (mmHg): High45
SBP Supine (mmHg): High15
DBP Standing (mmHg): Low01
DBP Standing (mmHg): High21
DBP Supine (mmHg): Low11
DBP Supine (mmHg): High13
Heart Rate Standing (beats/min): High104
Heart Rate Supine (beats/min): Low10
Heart Rate Supine (beats/min): High31
Body Temperature00
PrimaryNumber of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities

Twelve-lead ECG recordings were obtained after the participant was supine and at rest for at least 5 minutes. Criteria for identifying ECG measurements of potential clinical relevance included Rate: Tachycardia (Vent ≥110 beats per minute \[bpm\]; increase ≥15bpm), Bradycardia (Vent ≤ 60bpm; decrease ≥15bpm); Rhythm: Sinus tachycardia (≥ 110bpm; an increase of ≥15 bpm), Sinus bradycardia (≤ 60bpm; a decrease of ≥15 bpm), Supraventricular premature beat (not present at baseline and present post-baseline), Conduction: Right bundle branch block (not present at baseline and present post-baseline) and ST/T Morphology: Symmetrical T-Wave Inversion (not present at baseline and present post-baseline). The categories with at least one participant with clinically relevant ECG abnormalities are reported.

Time frame:
Baseline (current study) up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant Electrocardiogram (ECG) Abnormalities
ParticipantsPrior BrexpiprazolePrior Placebo
Rate: Tachycardia12
Rate: Bradycardia10
Rhythm: Sinus Tachycardia12
Rhythm: Sinus Bradycardia10
Rhythm: Supraventricular Premature Beat10
Conduction: Right Bundle Branch Block01
ST/T Morphology: Symmetrical T-Wave Inversion01
PrimaryNumber of Participants With Potentially Clinically Relevant Laboratory Test Abnormalities

Laboratory assessments included - serum chemistry including prolactin and thyrotropin, hematology, and urinalysis. Number of participants with potentially clinically relevant laboratory test abnormalities were reported as per criteria defined in SAP. The categories with at least one participant with clinically relevant value outside the normal range for laboratory assessments are reported.

Time frame:
Baseline (current study) up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant Laboratory Test Abnormalities
ParticipantsPrior BrexpiprazolePrior Placebo
Activated Partial Thromboplastin Time (sec): High62
Alanine Aminotransferase (U/L): High02
Aspartate Aminotransferase (U/L): High01
Bicarbonate (mEq/L): Low1415
Bilirubin (mg/dL): Low108
Bilirubin (mg/dL): High01
Calcium (mg/dL): Low01
Chloride (mEq/L): High20
Cortisol (ug/dL): Low79
Creatinine (mg/dL): High10
Glucose (mg/dL): Low01
Glucose (mg/dL): High10
Potassium (mEq/L): High13
Sodium (mEq/L): High20
Eosinophils/Leukocytes (%): High23
Hematocrit (%): Low01
Hematocrit (%): High10
Hemoglobin (g/dL): Low10
Hemoglobin A1C (%): High24
Leukocytes (10^9/L): Low62
Leukocytes (10^9/L): High01
Neutrophils (10^9/L): High02
Neutrophils/Leukocytes (%): Low82
Neutrophils/Leukocytes (%): High02
Platelets (10^9/L): High11
Prothrombin Intl. Normalized Ratio: High52
Prothrombin Time (sec): High32
Protein, Urine: Low1211
Protein, Urine: High1011
Prolactin (ng/mL): Low34
Prolactin (ng/mL): High12
Thyrotropin (uIU/mL): High20
PrimaryNumber of Participants With Potentially Clinically Relevant Abnormal Physical Examination Values

Physical examination included measurement of height and the examination of the head, ears, eyes, nose, and throat (HEENT); thorax; abdomen; urogenital; extremities; neurological; and skin and mucosae. Participants with abnormal values, as assessed by the investigator were reported.

Time frame:
Baseline (current study) up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant Abnormal Physical Examination Values
ParticipantsPrior BrexpiprazolePrior Placebo
Number of Participants With Potentially Clinically Relevant Abnormal Physical Examination Values64
PrimaryNumber of Participants With Suicidality as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS)

Suicidality as defined as at least one occurrence of suicidal ideation or suicidal behavior, was assessed using C-SSRS. The assessment included "yes" or "no" responses for 5 questions, each related to suicidal ideation (wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods, active suicidal ideation with some intent, active suicidal ideation with specific plan) \& suicidal behavior (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, suicide). Numeric ratings were provided for suicidal ideation: Score range of 1 (wish to be dead) to 5 (active suicidal ideation with specific plan and intent), higher total scores indicate more suicidal ideation; Suicidal behavior: Score range of 0 (no suicidal behavior) to 4 (actual suicide attempt), higher total scores indicate more suicidal behavior. Number of participants with at least one occurrence of suicidal ideation or suicidal behavior was reported.

Time frame:
Baseline (current study) up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Suicidality as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsPrior BrexpiprazolePrior Placebo
Number of Participants With Suicidality as Measured by Columbia-Suicide Severity Rating Scale (C-SSRS)42
PrimaryChange From Baseline in Simpson Angus Scale (SAS) Total Score at Week 2

SAS was used to evaluate extrapyramidal symptoms (EPS). The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point Likert scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where a higher score indicates a severe condition. Negative change from baseline indicates absence of symptoms.

Time frame:
Baseline and Week 2
Reported as:
Mean · score on a scale
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Week 2
score on a scalePrior BrexpiprazolePrior Placebo
Change From Baseline in Simpson Angus Scale (SAS) Total Score at Week 2-0.0 ± 0.50.0 ± 0.5
PrimaryChange From Baseline in SAS Total Score at Week 14

SAS was used to evaluate extrapyramidal symptoms (EPS). The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point Likert scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where a higher score indicates a severe condition. Negative change from baseline indicates absence of symptoms.

Time frame:
Baseline and Week 14
Reported as:
Mean · score on a scale
Change From Baseline in SAS Total Score at Week 14
score on a scalePrior BrexpiprazolePrior Placebo
Change From Baseline in SAS Total Score at Week 14-0.1 ± 0.70.2 ± 0.6
PrimaryChange From Baseline in SAS Total Score at Week 26

SAS was used to evaluate extrapyramidal symptoms (EPS). The SAS consists of a list of 10 symptoms of Parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia). Severity of each item was rated on a 5-point Likert scale, with a score of 0 (absence of symptoms) to 4 (severe condition). The SAS total score is the sum of the scores of all 10 items, ranging from 0 to 40 where a higher score indicates a severe condition. Negative change from baseline indicates absence of symptoms.

Time frame:
Baseline and Week 26
Reported as:
Mean · score on a scale
Change From Baseline in SAS Total Score at Week 26
score on a scalePrior BrexpiprazolePrior Placebo
Change From Baseline in SAS Total Score at Week 26-0.1 ± 0.9-0.0 ± 0.2
PrimaryChange From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Week 2

The AIMS is a 12-item scale. The first 10 items are rated on a Likert 5-point scale from 0 to 4 (0 = best, 4 = worst). An item score of 0, depending on specific item, means either "no abnormal Involuntary movement (AIM)" or "no incapacitation due to AIM" or "no awareness of AIM". An item score of 4 means either "severe AIM" or "severe incapacitation due to AIM" or "being aware of, and severe distress caused by AIM". Items 11 and 12 are related to dental status, taking dichotomous response: 0 = no and 1 = yes. AIMS movement score is the sum of the ratings for the first seven items with possible total scores of 0 to 28, where a higher score indicates a severe condition.

Time frame:
Baseline and Week 2
Reported as:
Mean · score on a scale
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Week 2
score on a scalePrior BrexpiprazolePrior Placebo
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Week 20.0 ± 0.000.14 ± 1.08
PrimaryChange From Baseline in AIMS Total Score at Week 14

The AIMS is a 12-item scale. The first 10 items are rated on a Likert 5-point scale from 0 to 4 (0 = best, 4 = worst). An item score of 0, depending on specific item, means either "no abnormal Involuntary movement (AIM)" or "no incapacitation due to AIM" or "no awareness of AIM". An item score of 4 means either "severe AIM" or "severe incapacitation due to AIM" or "being aware of, and severe distress caused by AIM". Items 11 and 12 are related to dental status, taking dichotomous response: 0 = no and 1 = yes. AIMS movement score is the sum of the ratings for the first seven items with possible total scores of 0 to 28, where a higher score indicates a severe condition.

Time frame:
Baseline and Week 14
Reported as:
Mean · score on a scale
Change From Baseline in AIMS Total Score at Week 14
score on a scalePrior BrexpiprazolePrior Placebo
Change From Baseline in AIMS Total Score at Week 140.0 ± 0.000.16 ± 1.15
PrimaryChange From Baseline in AIMS Total Score at Week 26

The AIMS is a 12-item scale. The first 10 items are rated on a Likert 5-point scale from 0 to 4 (0 = best, 4 = worst). An item score of 0, depending on specific item, means either "no abnormal Involuntary movement (AIM)" or "no incapacitation due to AIM" or "no awareness of AIM". An item score of 4 means either "severe AIM" or "severe incapacitation due to AIM" or "being aware of, and severe distress caused by AIM". Items 11 and 12 are related to dental status, taking dichotomous response: 0 = no and 1 = yes. AIMS movement score is the sum of the ratings for the first seven items with possible total scores of 0 to 28, where a higher score indicates a severe condition. A negative change from baseline indicates less symptoms.

Time frame:
Baseline and Week 26
Reported as:
Mean · score on a scale
Change From Baseline in AIMS Total Score at Week 26
score on a scalePrior BrexpiprazolePrior Placebo
Change From Baseline in AIMS Total Score at Week 260.00 ± 0.00-0.04 ± 0.19
PrimaryChange From Baseline in Barnes Akathisia Rating Scale (BARS) Score at Week 2

The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point Likert scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14. Lower scores indicate less symptoms.

Time frame:
Baseline and Week 2
Reported as:
Mean · score on a scale
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score at Week 2
score on a scalePrior BrexpiprazolePrior Placebo
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score at Week 20.02 ± 0.260.05 ± 0.30
PrimaryChange From Baseline in BARS Score at Week 14

The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point Likert scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14. Lower scores indicate less symptoms and negative change from baseline indicate less symptoms.

Time frame:
Baseline and Week 14
Reported as:
Mean · score on a scale
Change From Baseline in BARS Score at Week 14
score on a scalePrior BrexpiprazolePrior Placebo
Change From Baseline in BARS Score at Week 14-0.05 ± 0.220.05 ± 0.40
PrimaryChange From Baseline in BARS Score at Week 26

The BARS consists of 4 items related to akathisia: objective observation of akathisia by the investigator, subjective feelings of restlessness by the participant, subjective distress due to akathisia, and global clinical assessment of akathisia. The first 3 items were rated on a 4-point Likert scale, with a score of 0 (absence of symptoms) to 3 (severe condition) and the global clinical assessment was rated on a 6-point scale, with a score of 0 (absence of symptoms) to 5 (severe akathisia). Total score is the sum of the scores of all 4 items, ranging from 0 to 14. Lower scores indicate less symptoms and negative change from baseline indicate less symptoms.

Time frame:
Baseline and Week 26
Reported as:
Mean · score on a scale
Change From Baseline in BARS Score at Week 26
score on a scalePrior BrexpiprazolePrior Placebo
Change From Baseline in BARS Score at Week 260.00 ± 0.24-0.04 ± 0.19
PrimaryPercentage of Participants With Potentially Clinically Relevant Changes in Weight up to Week 14

Percentage of participants who had significant weight gain (≥ 7% increase in body weight relative to baseline) and significant weight loss (≥ 7% decrease in body weight relative to baseline) were reported.

Time frame:
Baseline up to Week 14
Reported as:
Number · percentage of participants
Percentage of Participants With Potentially Clinically Relevant Changes in Weight up to Week 14
percentage of participantsPrior BrexpiprazolePrior Placebo
Weight Gain >= 7%45.048.6
Weight Loss >= 7%0.00.0
PrimaryPercentage of Participants With Potentially Clinically Relevant Changes in Weight up to Week 26

Percentage of participants who had significant weight gain (≥ 7% increase in body weight relative to baseline) and significant weight loss (≥ 7% decrease in body weight relative to baseline) were reported.

Time frame:
Baseline up to Week 26
Reported as:
Number · percentage of participants
Percentage of Participants With Potentially Clinically Relevant Changes in Weight up to Week 26
percentage of participantsPrior BrexpiprazolePrior Placebo
Weight Gain >= 7%71.876.7
Weight Loss >= 7%0.03.3
PrimaryTime to Discontinuation Due to AE

The time to discontinuation due to AE was defined as the total number of days between the enrolment date and the discontinuation date. The time to discontinuation was analyzed using the Kaplan Meier curve.

Time frame:
Baseline (in current study) up to 21 days post last dose of study drug (up to approximately 29 weeks)
Reported as:
Median · days
Time to Discontinuation Due to AE
daysPrior BrexpiprazolePrior Placebo
Time to Discontinuation Due to AE83 (14 to 152)113 (54 to 140)
SecondaryMean Change From Baseline to Week 26 in Aberrant Behavior Checklist - Irritability (ABC-I) Subscale Score

The ABC is parent-reported rating scale designed to assess treatment effects on problem behavior in participants with intellectual disabilities. The ABC scale has 58 items, which divide into 5 subscales as follows:(1) Irritability, Agitation; (2) Lethargy, Social Withdrawal; (3) Stereotypic Behavior; (4) Hyperactivity, Noncompliance; and (5) Inappropriate Speech. Each of the 58 ABC items is rated on a 4-point scale (0 = not at all a problem; 1=the behavior is a problem, but slight in degree; 2=problem is moderately serious; 3=problem is severe in degree). The Irritability subscale (ABC-I) measures emotional and behavioral symptoms of ASD, including aggression toward others, deliberate self-injuriousness, temper tantrums, \& quickly changing moods. ABC-I total score is the sum of the ratings over 15 ABC items. Individual scores were summed, thus the ABC-I total score ranges from 0 to 45. Higher scores represent the worst condition. Negative change from baseline indicates less symptoms.

Time frame:
Baseline (current study), Week 26
Reported as:
Mean · score on a scale
Mean Change From Baseline to Week 26 in Aberrant Behavior Checklist - Irritability (ABC-I) Subscale Score
score on a scalePrior BrexpiprazolePrior Placebo
Mean Change From Baseline to Week 26 in Aberrant Behavior Checklist - Irritability (ABC-I) Subscale Score-5.47 ± 8.06-7.00 ± 8.36
SecondaryMean Change From Baseline to Week 26 in Clinical Global Impression - Severity (CGI-S) Scale Score

The CGI-S scale is a clinician-rated assessment that evaluates the severity of a participant's condition with a focus on symptoms of irritability on a 7-point scale. The investigator (or rater) answered the following question: "Considering your total clinical experience with this particular population, how ill was the participant at this time with regard to symptoms of irritability?" Response choices were 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill patients. The total score ranges from 0 to 7, where higher scores indicate worse condition. A negative change from baseline indicates less symptoms.

Time frame:
Baseline (current study), Week 26
Reported as:
Mean · score on a scale
Mean Change From Baseline to Week 26 in Clinical Global Impression - Severity (CGI-S) Scale Score
score on a scalePrior BrexpiprazolePrior Placebo
Mean Change From Baseline to Week 26 in Clinical Global Impression - Severity (CGI-S) Scale Score-0.78 ± 0.99-0.68 ± 0.94

Adverse events

Collected over From the first dose of study drug (in current study) up to 21 days after the last dose of study drug (up to approximately 29 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Prior Brexpiprazole0/49 (0%)2/49 (4.1%)17/49 (34.7%)
Prior Placebo0/46 (0%)1/46 (2.2%)11/46 (23.9%)
Most frequent serious events
Most frequent serious events
EventPrior BrexpiprazolePrior Placebo
Affective DisorderPsychiatric disorders0/491/46
DyskinesiaNervous system disorders1/490/46
Suicidal IdeationPsychiatric disorders1/490/46
Most frequent other events
Most frequent other events
EventPrior BrexpiprazolePrior Placebo
Weight IncreasedInvestigations5/498/46
SomnolenceNervous system disorders5/491/46
Increased AppetiteMetabolism and nutrition disorders2/494/46
Viral InfluenzaInfections and infestations4/490/46
GastroenteritisInfections and infestations3/490/46
IrritabilityPsychiatric disorders3/490/46

Baseline characteristics

Enrolled Sample included participants who completed the double-blind treatment period of the parent study 331-201-00148 (NCT04174365) and who gave consent/assent for participation into this open-label study and who also met all the eligibility criteria for this study.

Age, Continuous
Age, Continuous(years)Prior BrexpiprazolePrior PlaceboTotal
Mean10.0 ± 3.110.0 ± 3.110.0 ± 3.1
Sex: Female, Male
Sex: Female, Male(Participants)Prior BrexpiprazolePrior PlaceboTotal
Female4812
Male453883
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Prior BrexpiprazolePrior PlaceboTotal
Hispanic or Latino6814
Not Hispanic or Latino433881
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Prior BrexpiprazolePrior PlaceboTotal
Race — White373875
Race — Black or African American8210
Race — Asian134
Race — Native Hawaiian or Other Pacific Islander011
Race — Other325
Weight
Weight(kilogram (kg))Prior BrexpiprazolePrior PlaceboTotal
Mean41.6 ± 17.944.2 ± 18.342.9 ± 18.1
Simpson Angus Scale (SAS) Score
Simpson Angus Scale (SAS) Score(score on a scale)Prior BrexpiprazolePrior PlaceboTotal
Mean0.4 ± 1.90.2 ± 0.60.3 ± 1.4
Abnormal Involuntary Movement Scale (AIMS) Total Score
Abnormal Involuntary Movement Scale (AIMS) Total Score(score on a scale)Prior BrexpiprazolePrior PlaceboTotal
Mean0.06 ± 0.320.02 ± 0.150.04 ± 0.25
Barnes Akathisia Rating Scale (BARS) Score
Barnes Akathisia Rating Scale (BARS) Score(score on a scale)Prior BrexpiprazolePrior PlaceboTotal
Mean0.04 ± 0.200.09 ± 0.460.06 ± 0.35
08

Study locations

28 sites
  • Dothan Behavioral Medicine Clinic
    Dothan, Alabama 36303, United States
  • Southwest Autism Research and Resource Center
    Phoenix, Arizona 85006, United States
  • University of California San Francisco, Nancy Friend Pritzker Psychiatry
    San Francisco, California 94143-3132, United States
  • APG Research
    Orlando, Florida 32803, United States
  • Autism Assessment, Research, Treatment and Services (AARTS) center
    Chicago, Illinois 60612, United States
  • Research site
    Lake Charles, Louisiana 70629, United States
  • The Lurie Center for Autism
    Lexington, Massachusetts 02421-3114, United States
  • Research site
    Bloomfield Hills, Michigan 48302, United States
  • Thompson Center for Autism and Neurodevelopment
    Columbia, Missouri 65211, United States
  • Research site
    Saint Charles, Missouri 63304, United States
  • Alivation
    Lincoln, Nebraska 68526, United States
  • Center for Psychiatry and Behavioral Medicine Inc.
    Las Vegas, Nevada 89128, United States
  • Rutger's-New Jersey Medical Scholl Clinical Research Unit
    Newark, New Jersey 07103, United States
  • For additional information regarding sites
    Princeton, New Jersey 08540, United States
  • Bioscience Research
    Mount Kisco, New York 10549, United States
  • Research site
    New York, New York 10036, United States
  • Finger Lakes Clinical Research
    Rochester, New York 14618, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10314, United States
  • Research Site
    Avon Lake, Ohio 44012, United States
  • The Holloway Group, Inc
    Oklahoma City, Oklahoma 73116, United States
  • Access Clinical Trials
    Nashville, Tennessee 37203, United States
  • Research site
    Austin, Texas 78759, United States
  • Cedar Health Research
    Dallas, Texas 75251, United States
  • Research site
    San Antonio, Texas 78249, United States
  • UT Health San Antonio Long School of Medicine, Department of Psychiatry and Behavioral Sciences
    San Antonio, Texas 78289, United States
  • Family Psychiatry of the Woodlands
    The Woodlands, Texas 77381, United States
  • Woodstock Research Center
    Woodstock, Vermont 05091, United States
  • Core Clinical Research
    Everett, Washington 98201, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Mar 2023, 37 months.

Results were first posted in May 2024, 1 year 2 months after primary completion.

Of 15 phase 3 interventional studies under Autistic Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 37 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2020
First posted
Feb 6, 2020
StartActual
Jan 23, 2020
Primary completionActual
Mar 16, 2023
CompletionActual
Mar 16, 2023
Results first posted
May 30, 2024
Last update
May 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04258839
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Feb 6, 2020
Start date
Jan 23, 2020
Primary completion
Mar 16, 2023
Completion
Mar 16, 2023
Results posted
May 30, 2024
Last update
May 30, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion